» Articles » PMID: 16492776

Ligand-specific Allosteric Regulation of Coactivator Functions of Androgen Receptor in Prostate Cancer Cells

Overview
Specialty Science
Date 2006 Feb 24
PMID 16492776
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The androgen receptor not only mediates prostate development but also serves as a key regulator of primary prostatic cancer growth. Although initially responsive to selective androgen receptor modulators (SARMs), which cause recruitment of the nuclear receptor-corepressor (N-CoR) complex, resistance invariably occurs, perhaps in response to inflammatory signals. Here we report that dismissal of nuclear receptor-corepressor complexes by specific signals or androgen receptor overexpression results in recruitment of many of the cohorts of coactivator complexes that permits SARMs and natural ligands to function as agonists. SARM-bound androgen receptors appear to exhibit failure to recruit specific components of the coactivators generally bound by liganded nuclear receptors, including cAMP response element-binding protein (CBP)/p300 or coactivator-associated arginine methyltransferase 1 (CARM1) to the SARM-bound androgen receptor, although still causing transcriptional activation of androgen receptor target genes. SARM-bound androgen receptors use distinct LXXLL (L, leucine; X, any amino acid) helices in the p160 nuclear receptor interaction domains that may impose selective allosteric effects, providing a component of the molecular basis of differential responses to different classes of ligands by androgen receptor.

Citing Articles

N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review.

Chen Y, Lan T Front Pharmacol. 2024; 15:1451957.

PMID: 39359255 PMC: 11444995. DOI: 10.3389/fphar.2024.1451957.


MED1 induces M2 polarization of tumor-associated macrophages to aggravate breast cancer.

Shen Y, Zhou L, Xu M, Tan Z, Yao K, Wang W Genes Genomics. 2023; 45(12):1517-1525.

PMID: 37594664 DOI: 10.1007/s13258-023-01435-0.


Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer.

Chauhan G, Heemers H Cancers (Basel). 2021; 13(16).

PMID: 34439101 PMC: 8393938. DOI: 10.3390/cancers13163947.


CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.

Waddell A, Huang H, Liao D Cancers (Basel). 2021; 13(12).

PMID: 34201346 PMC: 8229436. DOI: 10.3390/cancers13122872.


Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.

Nyquist M, Ang L, Corella A, Coleman I, Meers M, Christiani A J Clin Invest. 2021; 131(10).

PMID: 33998604 PMC: 8121509. DOI: 10.1172/JCI146777.


References
1.
Smith C, Nawaz Z, OMalley B . Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol. 1997; 11(6):657-66. DOI: 10.1210/mend.11.6.0009. View

2.
Chen D, Ma H, Hong H, Koh S, Huang S, Schurter B . Regulation of transcription by a protein methyltransferase. Science. 1999; 284(5423):2174-7. DOI: 10.1126/science.284.5423.2174. View

3.
Torchia J, Rose D, Inostroza J, Kamei Y, Westin S, Glass C . The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 1997; 387(6634):677-84. DOI: 10.1038/42652. View

4.
Heery D, Kalkhoven E, Hoare S, Parker M . A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997; 387(6634):733-6. DOI: 10.1038/42750. View

5.
Perlmann T, Evans R . Nuclear receptors in Sicily: all in the famiglia. Cell. 1997; 90(3):391-7. DOI: 10.1016/s0092-8674(00)80498-5. View